Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

[News]

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

More... (http://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx)